Transaction DateRecipientSharesTypePriceValue
6th October 2020Bruce Downey252,394Conversion of derivative$0.00
6th October 2020Bruce Downey237,148Conversion of derivative$0.00
1st October 2020Steven C Gilman7,796Sale back to the issuer$0.00
1st October 2020Jo Ann Beltramello57,157Sale back to the issuer$0.00
1st October 2020Craig A Wheeler8,739Sale back to the issuer$0.00
1st October 2020Craig A Wheeler36,725Sale back to the issuer$0.00
1st October 2020Anthony M. Manning12,778Sale back to the issuer$0.00
1st October 2020Craig A Wheeler389,120Sale back to the issuer$0.00
1st October 2020Santiago Arroyo26Sale back to the issuer$0.00
1st October 2020Georges Gemayel14,090Sale back to the issuer$0.00
Momenta Pharmaceuticals
Momenta Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.


Momenta Pharmaceuticals, Inc. focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001.


Ticker: MNTA
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1235010
Employees: 118
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $191 M (0%)
Assets, Current: $457 M (-15%)
Property, Plant and Equipment, Net: $11 M (-6%)
Other Assets, Noncurrent: $38 M (0%)
Assets: $523 M (-15%)
Accounts Payable, Current: $5 M (-66%)
Accrued Liabilities, Current: $35 M (0%)
Liabilities, Current: $72 M (-32%)
Other Liabilities, Noncurrent: $55 M (0%)
Liabilities: $128 M (-21%)
Common Stock, Value, Issued: $12 Th (0%)
Common Stock, Shares, Issued: $119 Th (1%)
Retained Earnings (Accumulated Deficit): $1 B (9%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 M (266%)
Treasury Stock, Value: $31 Th (0%)
Treasury Stock, Shares: $6 Th (0%)
Stockholders' Equity (Parent): $395 M (0%)
Liabilities and Equity: $523 M (-15%)
Revenue: $7 M (0%)
Research and Development: $39 M (-46%)
General and Administrative Expenses: $25 M (-36%)
Operating Income/Loss: $57 M (-41%)
Other Income, net: $346 Th (-76%)